Loading...
Market
Will Cassava Sciences announce a new Alzheimer's drug candidate by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press releases from Cassava Sciences or major financial news outlets
Story
Cassava's Simufilam Fails ReThink-ALZ Phase 3 Trial; Shares Plunge 80%
Nov 25, 2024, 12:35 PM
Cassava Sciences announced on November 25th that its Phase 3 ReThink-ALZ trial of simufilam, a treatment for mild-to-moderate Alzheimer's disease, failed to meet co-primary endpoints. The drug did not show a significant reduction in cognitive or functional decline versus placebo. Consequently, the company plans to discontinue the second Phase 3 ReFocus-ALZ trial and the Open Label Extension study. Shares of Cassava Sciences fell over 80% following the announcement. The company stated that simufilam continued to demonstrate an overall favorable safety profile and has $149 million in cash reserves.
View original story
Similar markets
Yes • 50%
No • 50%
Successful with measurable cognitive improvement • 25%
Partially successful with some cognitive improvement • 25%
Unsuccessful with no cognitive improvement • 25%
Trial canceled or postponed • 25%
Results lead to renewed interest • 25%
Results confirm initial failure • 25%
Mixed reception from the scientific community • 25%
No significant impact • 25%
Yes • 50%
No • 50%
Favorable ruling for Cassava Sciences • 25%
Unfavorable ruling for Cassava Sciences • 25%
Settlement • 25%
Case dismissed • 25%
Below $1 billion • 25%
$1 billion to $1.5 billion • 25%
$1.5 billion to $2 billion • 25%
Above $2 billion • 25%